Compare Neurocrine Biosciences Inc (NBIX) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ServiceNow Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while ServiceNow Inc trades at $131.58 (market cap $138.75B). The key difference: ServiceNow Inc is far larger — about 8.8× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| NBIX | NOW | |
|---|---|---|
Market Cap | $15.77B | $138.75B |
Sector | Health | Technology |
52-Week High | $185.50 | $192.23 |
52-Week Low | $123.10 | $83.00 |
Enterprise Value | $15.78B | $142.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
ServiceNow (NOW) trades at $131.11, down 7.19% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew from $7.2B in 2022 to $13.28B in 2025, though net income margin has fluctuated. Positive sentiment is driven by AI integration and conference presentations, while high valuation ratios like a P/E of 83.88 present risks.
The outlook remains positive due to robust revenue growth and AI-driven business expansion, but elevated valuations and competitive pressures warrant caution. Analyst consensus is strongly bullish with a $141.46 price target, though investors should monitor execution risks and macroeconomic headwinds that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
